Connect with us


Police raid Lidl in Bavaria over CBD cookies.

Lidl signed a deal with The Green Dealers to provide CBD and THC free products to potentially 3350 stores



Lidl: A sign for German brand Lidl against a clear blue sky

Police raid German retailer Lidl over a collection of edibles containing no CBD or THC. The product has been removed from shelves as a precautionary measure.

German police have raided the Rosenheim branch of the grocery store Lidl in Bavaria over CBD cookies and other assorted products including cannabis energy drinks and hash brownies. The raid was reported in the digital newspaper,  München Abendzeitung.

Lidl, one of the largest retailers in the world launched their CBD products by advertising with colourful inserts that were posted to households. The adverts promoted the various edibles on the front of the mailers and products had only been on shelves for one week.

According to the advertisements, the 21 products were said to contain no THC or CBD but taste like hemp. It’s part of a deal with a start-up company, The Green Dealers and is meant to roll out in 3350 stores.

Full story on the Lidl and The Green Dealers million dollar cannabis deal at Cannabis Wealth

The products

The products were run at a discount at the start of the campaign. Cannabis cookies, ‘Mary & Juana’ were on sale for EUR 3.49 instead of the normal retail price of EUR 4.49. Milk and dark chocolates were sold under the same name with a 20 percent discount.

The cookies, brownies and chocolate bars from the brand are available in other shops. They are made with cannabis seeds and leaves. The company, Euphoria which makes cookies, muffins and other products. They also offer vodka made from cocaine leaves and absinthe.

READ MORE  Jane West - The mum who was fired for using cannabis built her own empire

Read more: Stop censoring CBD! New cannabis coalition aims to stop CBD marketing restrictions

German law

It is legal to buy or consume CBD products, but only if the THC value is below 0.2 percent. CBD is still part of the German narcotics act which means it cannot be advertised.

Speaking to München Abendzeitung, police spokesperson, Stefan Sonntag said: “Several articles have been secured.”

The items are currently being tested at the State Criminal Police Office in Munich even though they come from a manufacturer who produces THC-free products only.

This is the only company targeted for raids. There have been reports of hemp tea manufacturers and German chain store, Hanf Im Glück has also been raided. Hanf im Glück sell CBD vapes, animal products and beauty items.

In a statement to AZ, Lidl announced that all products have been removed from shelves:

“We can confirm that the authorities have currently initiated an investigation into individual products from our limited-time promotional range of hemp products. As a precautionary measure, we have taken all items off sale and are working closely with the authorities. “

European Lidl

This isn’t the first move into cannabis or CBD products by the German retailer. The company has sold locally grown cannabis for customers in Switzerland, the retailer sold a 1.5g box for 18 Swiss francs (£13.20) in 2018. Although this would have fallen under Swiss law, not German.

The product was labelled as a tobacco alternative and was made from flowers grown in greenhouses. They were on sale beside tobacco products but were double the price. Swiss law permits anyone over 18 to purchase and use cannabis containing no more than 1 percent of THC. The cannabis was supplied by The Botanicals, based in Thurgau, north-east Switzerland.

READ MORE  Fresh hopes for medical cannabis access under new Health Secretary Sajid Javid

Cannabis Health News has reached out to Lidl and Euphoria for comment.

Read more: Irish campaigner responds to doctors decision to potentially shun MCAP programme

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *


Rapper Lil’ Kim announces new cannabis brand ‘aphrodisiac’

The New York rapper becomes the latest celebrity to launch their own cannabis collection which is due in 2022.



Image: Instagram/lilkimthequeenbee

The singer has announced the launch of her own cannabis brand, Aphrodisiac which is being produced in partnership with Superbad inc.

Lil Kim’s new products will be available across California in 2022, although there is no official launch date announced.

The brand is being produced in collaboration with the innovative cannabis brand, Superbad inc. Superbad was established in 2020 combining cutting edge technology and sleek design for cannabis consumers. They currently have seven acres of indoor grow and a “state-of-the-art facility” employing over 200 people.

Kimberly Denise Jones who goes by her stage name, Lil’ Kim has been working on the brand for two years. She has also partnered with the brand CampNova, which offer vertically integrated marketing and a distribution platform.

The rapper wants the cannabis line to reflect her personal style and says she has personally tested her own products. The collection is tailored to Lil’ Kim’s own preference in genetics and strains.

Lil' Kim: A banner advert for Always Pure Organics

Lil’ Kim collection

There are plans to expand the range to other legal states such as Michigan, New Jersey and New York. Originally from New York, Lil’ Kim hopes to be able to release the collection in her home state.

In an interview with Forbes magazine, she said: “I’ve actually been working on this for about two and a half to three years. This is something that didn’t just come overnight. It’s something I’ve always wanted to do.”

Lil’ Kim is the latest celebrity to enter the cannabis space with her own collection. Earlier this year, Justin Bieber announced he would be releasing a collection of pre-rolls called Peaches with premium brand Palms. The products are currently available in California, Nevada, Massachusetts and Florida.

READ MORE  OPINION: The highs and lows of prescribing medical cannabis down under

In a press release, he stated: “I’m a fan of Palms and what they are doing by making cannabis approachable and helping to destigmatise it — especially for the many people who find it helpful for their mental health.”


Image rights: Lil’ Kim

Continue Reading


Always Pure Organics: A day in the life with Chikako Yoshida

Regional Director of Asia, Chikako Yoshida, gives us a glimpse of her typical workday and discusses working in cannabis.



Always Pure Organics: A man and a woman working on a laptop.

Chikako Yoshida, regional director of Asia for Always Pure Organics shares her experience of working in the cannabis industry.

Always Pure Organics is excited to give you a glimpse behind the curtain once again.

Join us for our latest episode of a Day in the Life, in which regional director of Asia, Chikako Yoshida discusses her experience working for Always Pure Organics and in the cannabis industry.

Always Pure Organics: A woman walking down a white and yellow hallway

In this episode, we follow our Regional Director of Asia, Chikako Yoshida, as she takes us through her typical workday. Having previously worked in counterterrorism for the United Nations, Chikako joined the APO team in May 2020. Chikako has such an interesting story to tell, we’re honoured to have her on the team as she embodies our mission to cultivate cannabis acceptance and accessibility worldwide. 

Chikako Yoshida said: “Upon learning about the power of cannabis and seeing the high potential growth of Always Pure Organics, I decided to change career from preventing illicit drugs to promoting cannabis to help people in need. I feel that by joining APO, I can help fulfil my life’s mission to support children and their families who fight against illness and sickness by providing them with cannabis products.”

Read more: Always Pure Organics achieves COSMO standard

Always Pure Organics: A banner explaining how the collaborative post works

READ MORE  “It got me back on my feet”: The story behind Cumbria’s first CBD company
Continue Reading


CBGA may be ‘more potent’ than CBD against seizures in Dravet syndrome

Dr Lyndsey Anderson said there is more to explore when it comes to creating more treatment options for Dravet syndrome.



Seizure: A row of test tubes containing CBGA oil with a doctors white gloved hand holding one up to the light

Scientists say they have found the ‘Mother of all cannabinoids’ which may help to reduce seizures in Dravet syndrome.

A new study on mice from the University of Sydney found that three acidic cannabinoids found in cannabis reduced seizures in Dravet syndrome, an intractable form of childhood epilepsy.

The three cannabinoids are cannabigerolic acid (CBGA), cannabidivarinic acid (CBDVA), cannabigerovarinic acid (CBGVA). All three but CBGA in particular “may contribute to the effects of cannabis-based products in childhood epilepsy” noted the researchers and were found to potentially have ‘anticonvulsant properties.”

The study marks the first time that three acidic cannabinoids were found to potentially help reduce seizures for Dravet syndrome.

Speaking with Cannabis Health News, the lead author of the study, Dr Lyndsey Anderson, said: “We found that CBGA exhibited both anticonvulsant and pro-convulsant effects. CBGA was more potent than CBD against febrile seizures in a mouse model of Dravet syndrome. We also found that a combination of CBGA and clobazam was more effective than either treatment alone. Additionally, we found that CBGA was anticonvulsant in the maximal electroshock acute seizure model, a model for generalized tonic-clonic seizures.”

She added: “CBGA did, however, present some proconvulsant effects. The frequency of spontaneous seizures in the mouse model of Dravet syndrome was increased with a high dose of CBGA. Also, CBGA was proconvulsant in the 6-Hz acute seizure model, a model of focal, psychomotor seizures.”

Although CBGA shows promise, Dr Anderson also stressed that it needs more research before it can replace CBD. She cautioned that Dravet syndrome patients may still need to proceed with caution.

READ MORE  Swiss producer’s UK move

“Artisanal cannabis-based products are believed to reduce seizures in Dravet syndrome patients,” she said. “As these oils contain rare cannabinoids like CBGA, it is possible CBGA then contributes to the anticonvulsant effects of these artisanal cannabis oils. However, there were proconvulsant effects observed with CBGA, suggesting that Dravet syndrome patients may need to proceed with caution. The proconvulsant liability of CBGA would need to be addressed before it replaced CBD as an anticonvulsant.”

What is CBGA?

Sometimes referred to as ‘the mother of all cannabinoids,’ CBGA is the precursor molecule to many different cannabinioids including CBD and THC. It is thought to help some diseases such as colon cancer, metabolic disease and cardiovascular disease. It is a non-intoxicating cannabinoid much like CBD.

Dr Anderson explains that more research is needed to explain how the three cannabinoids work together.

“We don’t know how they work together yet,” she said. “We found that CBGA, CBDVA and CBGVA were all individually anticonvulsant against thermally induced seizures in the mouse model of Dravet syndrome. We did not investigate whether a combination of these three cannabinoids would result in a greater anticonvulsant effect than either cannabinoid alone. Future work will definitely explore this possibility.”  

CBGA future research

This isn’t the end of the research into CBGA for Dravet Syndrome. Dr Anderson said there is more to explore when it comes to creating more treatment options for Dravet syndrome.


She said: “Next on the horizon for this research is to explore whether the anticonvulsant properties of CBDVA and CBGVA translate to other seizure types including spontaneous seizures in the mouse model of Dravet syndrome. Additionally, we have extensively interrogated the anticonvulsant potential of individual cannabinoids and identified ten with anticonvulsant properties.”

READ MORE  Jane West - The mum who was fired for using cannabis built her own empire


“We are now interested in investigating what happens when we combine these anticonvulsant properties. It remains an open possibility that greater anticonvulsant effects are achieved when the cannabinoids are administered in combination.”

The study was recently published in the British Journal of Pharmacology (DOI: 10.1111/bph.15661)

Continue Reading


Cannabis Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. All content on this site is intended for educational purposes, please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2021 H&W Media Ltd.